Current Report Filing (8-k)
08 6월 2016 - 3:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 7, 2016
___________________
FLAMEL TECHNOLOGIES S.A.
(Exact name of registrant as specified in
its charter)
___________________
Republic of France
(State or Other Jurisdiction
of Incorporation)
|
000-28508
(Commission File Number)
|
98-0639540
(I.R.S. Employer
Identification No.)
|
Parc Club du Moulin à Vent
33, avenue du Docteur Georges Levy
69200 Vénissieux France
(Address of Principal Executive Offices)
|
|
Not Applicable
(Zip Code)
|
Registrant’s telephone number, including
area code:
011 +33 472 78 34 34
___________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
£
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
£
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
£
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
£
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01 Regulation FD Disclosure.
On June 7, 2016, Flamel Technologies S.A. (the “Company”)
intends to make a presentation at the Jefferies 2016 Healthcare Conference in New York, New York. A copy of the Company’s
complete slide presentation to be used at the Conference is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
As previously announced, the Company’s presentation will be webcast live and can be accessed by visiting the Investor section
of the Company’s website at http://www.flamel.com/investors. A replay of the presentation, together with the complete slide
presentation, will also be available and archived for at least 30 days on the website following the event.
The information responsive to Item 7.01 of this Form 8-K,
including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as may be expressly set forth by specific
reference in such a filing.
Item
9.01 Financial Statements and Exhibits.
99.1
|
|
Form of Slide Presentation of Flamel Technologies S.A. as of June 7, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
FLAMEL TECHNOLOGIES S.A.
|
|
|
|
By:
|
/s/ Phillandas T. Thompson
|
|
|
Phillandas T. Thompson
|
|
|
Senior Vice President, General Counsel and Corporate Secretary
|
Date: June 7, 2016
Exhibit Index
99.1
|
|
Form of Slide Presentation of Flamel Technologies S.A. as of June 7, 2016.
|
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024